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Abstract
Background: Depression and dementia are major public health problems in the UK. Depression in early-stage
dementia is very common and significantly reduces quality of life, speeds cognitive decline and increases functional
impairment. Mindfulness-Based Cognitive Therapy (MBCT) is an effective depression prevention programme, and the
National Institute for Clinical Excellence (NICE) has suggested that MBCT is a priority for implementation. Alongside this,
there is emerging evidence demonstrating promising results in relation to the benefits of adapted mindfulness
interventions for people with dementia, suggesting that it could be beneficial in reducing depressive symptoms and in
slowing deterioration in cognitive functions such as sustained attention, distraction inhibition and task switching.
Methods: The design is a single-blind randomised controlled feasibility trial. Participants with mild to moderate
depression and early stages of dementia will be recruited from the participating memory services. Participants will
receive either immediate or delayed access to an 8-week MBCT programme. Participants will be assessed by a blind
assessor and complete cognitive and mood-related outcome measures before and after the intervention. This
feasibility study will test the trial design and assess recruitment, retention, acceptability and adherence, as well as
providing preliminary efficacy data.
Discussion: This study will inform the design and sample size for a future full randomised controlled trial (RCT), which
will be carried out to determine the effectiveness of the intervention in reducing depressive symptoms in people with
early stages of dementia.
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Background
Depression and dementia are major widespread public
health problems in the UK, with the numbers of people
with dementia set to rise to 1.7 million by 2051 [1]. It is
estimated that 50% of people with dementia experience
some symptoms of depression, and the rate of persist-
ence of symptoms is high [2]. Evidence suggests that the
onset of depression is linked to a dementia diagnosis [3].
Comorbid depression in dementia (i) significantly
reduces quality of life [4], (ii) speeds cognitive decline
[5], (iii) increases functional impairment and the need
for nursing home placements [6], (iv) is associated with
higher mortality rates [7], (vi) increases carer stress [8]
and (vii) is costly for health resources, with an increased
use of expensive inpatient beds [9].
The Improving Access to Psychological Therapies
(IAPT) programme has successfully rolled out services
providing Cognitive Behavioural Therapy (CBT) in
England [10], with good outcomes in terms of depressive
symptom reduction [11]. The government has now
pledged to increase access to evidence-based therapies
to all patient groups, including older people and people
with dementia [12]. However, there is currently little evi-
dence for the benefit of psychological interventions for
depression in people with dementia [6]. A recent
meta-analysis has concluded that Mindfulness-Based
Cognitive Therapy (MBCT) is an effective depression
prevention programme for people without dementia, but
with a history of recurrent depression [13]. In addition,
the National Institute for Clinical Excellence (NICE) has
suggested that MBCT is a priority for implementation.
Alongside this, there is emerging evidence demonstrat-
ing promising results in relation to the benefits of
adapted mindfulness interventions for people with
dementia, suggesting that it could be beneficial in redu-
cing depressive symptoms and in slowing deterioration
in cognitive functions such as sustained attention, dis-
traction inhibition and task switching [14].
Recently, evidence from an adapted mindfulness inter-
vention feasibility study for people with dementia in care
homes (n = 31) showed that a modified mindfulness
intervention was feasible and that it led to significant
improvements in quality of life [15]. There were no
significant changes in mood. However, the study did not
actively recruit people with depression and a third of the
participants from the intervention group who were in
the clinically depressed range at baseline moved out of
the range at follow-up. In contrast, none of the partici-
pants in the control arm did, suggesting that the inter-
vention should be further tailored and target people with
comorbid depression and dementia.
This current study will be the first to investigate the
feasibility and potential efficacy data of MBCT in people
with comorbid dementia and depression, using
qualitative and quantitative methods as recommended
by the Medical Research Council [16].
The aim of this study is to provide evidence for the
feasibility of conducting a fully powered RCT to evaluate
a complex psychological intervention for depression in
people with early stages of dementia. Feasibility will be
evaluated in it in terms of rates of recruitment, retention
and adherence to treatment protocol. The potential
efficacy of the intervention will also be estimated.
Methods/design
Design
A single-blind randomised feasibility trial will be carried
out to test the delivery of an MBCT intervention for
people with mild to moderate depression and comorbid
early stages of dementia. In this RCT, 50% of partici-
pants will be randomly allocated to the immediate group
(IA) and will receive MBCT immediately. The remaining
50% of participants will be allocated to the delayed
access control (DAC) group. Both arms will receive treat-
ment as usual. Participants will be assessed by blinded as-
sessors that will not be involved in the delivery of the
intervention at any point. Assessors will provide explicit
reminders to the participants before the assessment visit
so that participants do not disclose group allocation inad-
vertently. The assessor will also record their impression of
which arm of the trial the participants belong to and their
confidence in that prediction on completion of the follow-
up assessments. This will enable us to assess whether in-
advertent loss of blinding leads to bias.
Alongside the running of the study, a progress evalu-
ation will be carried out by interviewing participants
taking part in the groups in order to gather qualitative
information that can support and enhance the quantita-
tive findings of the feasibility study. In order to gather
in-depth data regarding people with dementia’s experi-
ence of attending a mindfulness group, participants that
attended the group will be invited to a semi-structured
interview after the group. Approximately 10–12 inter-
views with group participants and family caregivers will
be conducted. Carers of participants will be invited to
further examine whether potential benefits of the MBCT
intervention were generalised to other areas that relate
to activities of daily living such as engagement in home-
based practice and improvements observed at home.
Study setting and location
Participants will be recruited and identified from memory
services in North East London NHS Foundation Trust
and memory services in Oxleas Foundation Trust.
Target group and sample size
As this is a feasibility pilot trial and there is limited re-
search on the effects of mindfulness-based interventions
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for depression for people with dementia, it was difficult
to estimate the likely effect size. We took a sample of 32
participants, 16 per group, as this was considered
feasible for the requirements of this pilot trial [17].
Inclusion criteria
People meeting the inclusion criteria are those treated
for or with a diagnosis of mild depression and a diagno-
sis of mild to moderate dementia according to DSM-IV
criteria with a Mini Mental State Examination (MMSE)
[18] of 18 or above.
Exclusion criteria
People meeting the exclusion criteria are those who (1)
have congenital learning disability; (2) present with
severe depression or high risk of self-harm (e.g. suicidal
intent) requiring urgent intervention; (3) are within
2 months of bereavement; (4) are involved in other psy-
chosocial intervention research; or (5) have a diagnosis
of psychosis.
Intervention
The MBCT treatment protocol will be adapted from
MBCT for the prevention of depression relapse [19].
The main adaptation will be the substitution of longer
length of meditation practices with shorter ones, discus-
sion of patient’s mood and cognitive symptoms in-ses-
sion and encouraging participants to use formal
mindfulness exercises as well as informal mindfulness
when distressing situations arise during the week. We
will also shorten the length of the mindfulness medita-
tion for home practice from 45 to 15–20 min and will
increase attention to distress from memory problems
during in-session and at-home exercises. The adapted
MBCT will consist of eight, weekly 1 h and half group
sessions, which will include skills training and in-class
practice. Specific in-class mindfulness exercises will in-
clude (a) ‘mindful eating’ (the ‘raisin exercise’), (b) ‘body
scan’ exercise, (c) ‘mindful stretching’ and (d) sitting
‘mindfulness’ meditation exercises with various objects
(breath, body, sounds, emotional states, thoughts). The
programme will incorporate daily assignments of ‘for-
mal’ home practice of mindfulness techniques (using
15–20-min audio-recordings as well as ‘informal’ exer-
cises to integrate mindfulness into everyday experiences
(e.g. eating, walking and brushing teeth). Participants
will be instructed to practise mindfulness exercises aided
by audio-recordings at least 5 days a week, as well as
practising mindfulness throughout the day (e.g. while
walking, eating, showering), for an additional 10–15 min
a day, for a total of 25–40 min of total practice per day.
Patients will be ask to record daily practice times in
homework logs which will be collected each week, in
which they will check which audio-recording(s) they had
listened to that day and how much time they had spent
doing other mindfulness practice throughout the day. A
weekly telephone call by a member of the team will aim
to support home practice.
Procedure for recruitment and intervention delivery
The researchers will present information about the study
(rationale, inclusion and exclusion criteria, etc.) to the
managers of the memory clinics (six in total). They will
then discuss the feasibility of running the study in their
service (e.g. available transport for participant, expected
attrition rate for groups in the service), and if they agree
to take part, they will start identifying suitable partici-
pants for the study.
Participants will then be informed of the study by their
clinical leads from the different memory services that
have agreed to take part in the study, and after express-
ing an interest in the study, potential participants will be
asked to complete eligibility pack which will include a
participant information sheet along with a consent form.
Participants will have the opportunity to ask questions
about the study by phone, email or post before being
asked to complete the consent form. Until eligibility has
been assessed and informed consent has been given, in-
dividuals will not be able to begin participation in the
study.
People with dementia meeting the inclusion criteria
and who consent to take part in the study, giving signed
informed consent in accordance with the provisions of
the Mental Capacity Act 2005 will be included in the
study. Clinical psychologist trainees that will be involved
in the process will receive informed consent and Mental
Capacity Act training. Where the participant’s level of
impairment increases, so that they were no longer able
to provide informed consent, the provisions of the Men-
tal Capacity Act 2005 will be followed. The initial giving
of informed consent will provide an indication of the
person’s preference for participation in the research, and
the family caregiver’s viewpoint will also be sought. If
the person with dementia shows discomfort at any point
with the assessments or their participation in the groups,
they will be discontinued.
Included participants will complete baseline assess-
ment and be randomised into either the IA and will re-
ceive MBCT immediately or the DAC group.
Randomisation will take place remotely by an independ-
ent member of the Research and Development Depart-
ment using the online software sealedenvelop.com.
Taking up or declining the study will not affect the usual
support and treatment they receive.
The two clinical researchers aim to run two MBCT
groups each, two at each site with approximately eight
participants in each. The clinicians running the groups
will monitor the feasibility of recruiting participants (for
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both IA and DAC groups) within the given time frame.
This will ideally include 16 participants in each of the
two locations.
At least two clinicians have been allocated to each of
the groups so that in the event that a group facilitator is
unavailable (e.g. leave, sickness), the remaining facilitator
will run the group alongside co-facilitators.
The qualitative interviews with participants and
their carers will be conducted within 3 weeks of the
groups having been completed. As such, it is expected
that all data collection will have been completed by
December 2016.
Treatment as usual
Usual care will be the same for both groups and involve
usual GP and memory service support, anti-depressant
medication, old age psychiatry review and community
psychiatric nurse appointments. For both groups, we will
record the care received to enable a full description of
treatment as usual.
Outcome measures
The primary outcome measures will assess feasibility
outcomes and be:
(a)Recruitment rate (incorporating willingness of
patients to be randomised and practicality of the
MBCT intervention)
The recruitment will be deemed feasible if it is possible
to recruit the required 32 participants in the given time
frame of 4 months (June 2016–September 2016).
(b)Retention rate (incorporating acceptability of the
therapy)
The attrition and retention rates will be assessed and
defined as the number of sessions completed and
people assessed at follow-up, including details of
withdrawals. We will judge an acceptable completion
rate as 55% of people completing four or more of
the eight course sessions and a follow-up completion
rate of at least 75%.
(c)Incidence of adverse events
We will be collecting details of any adverse events
that might arouse from evaluations and or delivery
of the intervention.
(d)Acceptability of the developed MBCT programme
We will be using qualitative interviews in order to
further assess the acceptability and perceptions of
the users in relation to the intervention, and its
results will inform the final design of the
intervention and consider this intervention as
acceptable for this client group.
(e)Acceptability of the clinical outcome measures for
inclusion in the study
We will be assessing the feasibility of the outcome
measures by exploring the missing data from the
measures used and examine the inclusion exclusion
rates from the recruitment process, and this will
inform future RCT trial design.
The secondary outcome measures will assess patient-
and carer-centred outcome measures and be conducted
by the assessor in a private room in the memory clinic
or in the participant’s home. The following measures will
be completed before and after the intervention (around
3 months) and 6-month post intervention.
(a)Cornell Scale for Depression in Dementia (CSDD) [20]
Depression will be assessed using the CSDD [20], a
19-item clinician-administered instrument. Each
item has a 3-point scale (0 = absent, 1 = mild or
intermittent, 2 = severe) with scores ranging from
0–38. The clinical cut-off for significant depressive
symptoms is a score of 8 and above [18].
(b)Patient Health Questionnaire (PHQ-9) [21]
PHQ-9 is a freely available mood rating
questionnaire consisting of nine questions mirroring
DSM-IV depression diagnostic criteria, and each
rated 0–3 giving a maximum score of 27. Cut-off
scores are used to label depression severity as 0–4,
minimal depression; 5–9, mild depression; 10–14,
moderate depression; 15–19, moderately severe
depression; and 20–27, severe depression.
(c)Quality of Life–Alzheimer’s Disease Scale:
Participant Version (QoL-AD) [22]
Quality of life will be measured using the Quality of
Life–Alzheimer’s Disease (QoL-AD) scale [22], a
13-item self-report questionnaire. Information about
several areas was gathered from the PWD and
their carer, such as physical health, mood,
friends, fun, self and general life. The measure
has excellent internal consistency and inter-rater
reliability. The content, criterion and construct
validity are good [23].
(d)Cognitive and Affective Mindfulness Scale (CAMS-R)
The Cognitive Affective Mindfulness Scale (Revised)
[24] is a 12-item self-report questionnaire that
measures trait mindfulness in day-to-day experience.
Scores range from 0 to 48, with higher scores indicating
higher levels of mindfulness. The measure was used in
the aforementioned pilot study [25].
(e)Generalised Anxiety Disorder 7-item (GAD-7) scale [26]
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The GAD-7 is a 7-item questionnaire focusing on
symptoms of anxiety experienced in the past 2 weeks.
Each item is rated according to the frequency of the
described problem.
(f ) Rating Anxiety in Dementia (RAID) [27]
Anxiety will be assessed using the RAID scale [27],
an 18-item clinician-administered instrument. Each
item is rated on a 4-point scale (0 = absent, 1 = mild
or intermittent, 2 = moderate, 3 = severe) with scores
ranging from 0 to 54. The clinical cut-off for significant
clinical anxiety was a score of 11 and above. The RAID
scale is the most appropriate measure for assessing
anxiety in PWD [28].
Weekly measures
PHQ-9, GAD-7 and CSDD will be collected after each
mindfulness session, in line with the service protocol.
Carer measures
This will be conducted by the assessor in a private room in
the memory clinic or in the participant’s home. The asses-
sor will ask a member of staff or family member questions
about the relevant participant’s, mood, anxiety and quality
of life. The information obtained will be used in combin-
ation with the information gathered from the interview
with the participant to complete the following assessments:
(a)Cornell Scale for Depression in Dementia [20]
(b)Quality of Life–Alzheimer’s Disease Scale: Carer
Version [22]
(c)Rating Anxiety in Dementia (carer version) [27]
Statistical analyses
Baseline characteristics will be summarised for all partic-
ipants, the IA and DAC groups separately. Participant
uptake of and adherence to the intervention, defined as
the number of sessions completed and the number of
support sessions participants take part in, as well as data
follow-up rates, will be summarised and presented as
percentages. To assess potential efficacy in each group
separately, data will be entered into SPSS and analyses
will be conducted using SPSS statistics for Windows
(Version 24; IBM Corp.). Although determining differ-
ences in clinical outcomes between the three arms is not
the primary purpose of this trial, comparisons will be
undertaken to investigate the feasibility of studying these
outcomes and to calculate estimates for the likely effect
sizes and 95% confidence intervals. As recommended in
guidelines for good practice for the analysis of pilot
studies [29], the focus of the results will be on the esti-
mates of the treatment effects rather than on statistical
significance, and as such, no hypothesis testing will be
undertaken. The qualitative interviews will be analysed
qualitatively using thematic analysis [30] to identify
emerging themes from within the data.
Finally, a power calculation using Gpower 3 [31] will
be carried out to determine the required sample size for
a future RCT.
Ethical considerations
Ethical approval has been granted by the HRA London City
and East REC, with REC approval number 16/LO/0578.
Confidentiality
Data collected by the research team will be kept either
on fingerprint or password-locked memory sticks, on
fingerprint identification laptops, stored in a locked
filing cabinet in the researcher’s office on the site of
University College London or will be saved on a secured
network space that only the researchers have access to.
Personally, identifying information will be removed from
the main electronic data files for analysis by the re-
searchers. A coded file with sensitive data will be stored
separately.
Discussion
Importance of the project
Depression and early dementia tend to present at the
same time and are major widespread public health prob-
lems in the UK. However, currently, there is no evidence
available for a beneficial treatment that can be offered to
this population. This novel project will determine
important factor imperative in the consideration of a
future RCT design such as recruitment, adherence, ac-
ceptability and follow-up rates of the MBCT group for
depression in people with early stages of dementia. We
hope that recruiting and identifying people with demen-
tia from memory services that present with mild to
moderate levels of depression who might otherwise fail
to engage in traditional NHS-based primary psycho-
logical services for depression will help to address the
wider treatment gap in postdiagnostic services for people
with dementia. The design allows a detailed description
of those recruited, in order to understand the age,
current and past treatments and severity and chronicity
of depression amongst those recruited.
If this study shows that the trial design is feasible,
then, this will lead to a larger, funded RCT of the inter-
vention, which may have important implications for sup-
porting people with early stages of dementia and create
a pathway for postdiagnostic interventions for dementia.
Benefits to participants
Participation within this research study will allow people
with early stages of dementia presenting mild to
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moderate depression to participate and engage in an
MBCT programme aimed at reducing depression.
Research has provided us with empirical evidence that
the proposed approach is effective in aiding a variety of
problems related to depression in those without demen-
tia and that it might be a useful approach for people
with early stages of dementia.
Results from this research will be used to indicate
whether the intervention is an acceptable resource for
people with early stages of dementia and comorbid de-
pression. By assessing the acceptance and feasibility of
the intervention for this population, we will be able to
gain a key insight as to how such an intervention can be
best delivered to individuals and details in relation to
how to implement it within the NHS.
In collaboration with Oxford Mindfulness Centre,
public engagement and knowledge exchange in different
populations, and their expert clinicians and researchers,
will be able to assist our intervention clinicians in case
they may need additional help. They are fully committed
to helping with this study, and they have granted the
study team to access their intervention materials for this
feasibility study. Working with OMC at this early feasi-
bility stage will lay a foundation for the future large RCT
which, if it is successful, will provide support for the
evaluation and introduction of MBCT in the NHS as an
additional psychological intervention to offer to people
with early stages of dementia and depression and a vi-
able option for depression postdiagnosis.
Dissemination
Dissemination will include an executive summary, open
access journal publications and conference presentations.
The main journal publication will present the study find-
ings with the data being used to inform the development
of the full RCT protocol. A simple feedback sheet infor-
mation in relation to the results of the study will be sent
to all participants who have taken part. The findings will
also be disseminated to the Oxford Mindfulness Centre in
the form of a report and an oral presentation. Oxford
Mindfulness Centre will then disseminate the results in-
ternally. We will also disseminate findings via the newslet-
ters on the widely used www.omc.com website.
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